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1. Introduction
Nanotechnology is a revolutionary field of micro manufacturing involving physical and
chemical changes to produce nano-sized materials. The word “nano” is a Latin word meaning
“dwarf”. Mathematically a nanometer is equal to one thousand millionth of a meter [1]. A
nanomaterial consists of aggregated as well as unbound particles. Nanotechnology in scientific
terms is defined as the science which deals with processes that occur at molecular and atomic
level or at nanolength size. It involves designing, synthesis and characterization of material
structure by controlling the shapes and sizes at nano scale. The conversion of a particle to nano
scale size changes the properties of the material such as increase in surface area, dominance
of quantum effects often associated with minute sizes, higher surface area to volume ratio etc.
and varies material’s magnetic, thermal and electrical property. For example, copper which is
opaque at macro scale becomes transparent at nano scale. Similarly the properties of gold at
nanoscale causes change in melting point from 200°C to 1068°C and colour changes from
yellow to blue to violet along with the change in its catalytic property [2]. Nanoparticles are
persistent in nature as well. Functional proteins may be classified as nanoparticles. Some
biological system consists of nanoparticles which are devoted to locomotory function. The
colours on butterfly’s wings are due to light being bounced off nanoscale layers in the structure
of the wings. The red and yellow colours seen at sunset are also due to nanoparticles [3]. Super
paramagnetic iron oxide less than 50 µm are used for imaging of organs. They can be even
used for treating complicated brain disorder bio-imaging at nano scale size [9].
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Indian craftsman and artisan used nanotechnology for designing weapons in early times. The
first observation and size measurement of nanoparticle were carried out using an ultra
microscope by Richard Zsigmondy in 1902. The term nanotechnology was first time used by
a researcher named Norio Taniguchi in University of Tokyo in 1974. In 1980 the inventions of
two atoms further advanced the field of Nanotechnology. In 1985 fullerene C60 was discovered
by Kroto’s and Smalley’s research team. In 1991 carbon tubes were discovered by Saumio lijima
and by 2000 National Nanotechnology Initiative (NNI), The United States was launched which
paved the way for future development in nanotechnology [2].
Nanotechnology may be considered as one of the main propellants for technological, econom‐
ical change as industrial competeition. Nanotechnology has integrated various disciplines
including biomedicine, engineering and technology. Nanotechnology is being used for
improving the existing products and to create new products. The strength can be varied
accordingly with the requirements of engineering. It can be used to make the water cleaner by
remediation to remove its pollutant. It has helped to clean the environment by removing
pollutants and has generated cleaner and cheaper energy. It has improved the healthcare
system by introducing new devices for diagnosis, monitoring, treatment of diseases and drug-
delivery [1].
Nanomaterials have wide applications in pharmaceutical sciences and technology. Few other
predominant areas of use of nanotechnology are in drug delivery, and as diagnostic imaging
and biosensor. These devices of nanoscale size are popularly known as nanomedicine. Thus
nanomedicines are sub-micron size materials (<1µm) which are used for treatment, monitoring
and diagnostic purposses. In the present chapter we will discuss on the current status and
future strategies of nanosize drug delivery systems.
2. Significance of nanomaterials in drug delivery
There are many reasons for which nanoscale size drug delivery systems are attractive to
formulation  scientists.  The  most  important  reason  is  that  number  of  surface  atoms  or
molecules to the total number of atoms or molecules increases in drug delivery systems.
Thus  the  surface  area  increases.  This  helps  to  bind,  adsorb  and  carry  with  other  com‐
pounds such as drug, probes and proteins. The drug particles itself can be engineered to
form  nanoscale  size  materials  too  [4].  The  nanosize  device  systems,  sizes  smaller  than
eukaryotic or prokaryotic cells,  can eventually much more in amount reach in generally
inaccessible areas such as cancer cells, inflamed tissues etc. due to their enhanced permea‐
bility and retention effect (EPR) and can impair lymphatic drainage thus that can be used
for administration of genes, proteins through the peroral route of administration [5]. They
can be used to target the reticuloendothelial cells, thereby facilitating passive targeting of
drug to the macrophages of liver and spleen and thus enabling a natural system for treating
intracellular infections [6]. The nanomaterials used for the purpose should be soluble, safe
and biocompatible as well as bioavailable. They should not occlude blood vessel and less
invasive and the toxicity associated with the nanomaterials  for  drug delivery should be
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very low so that they can be used to target the specific diseased tissue in a safe concentra‐
tion  [7].  They  need  protecting  drug  from  enzymatic  and  hydrolytic  degradation  in  the
gastrointestinal tract and help in bypassing the “first-pass” metabolism in the liver. They
generally remain in the circulation for longer time especially those coated with hydrophil‐
ic polymers and hence suitable for enhancing the efficacy of drugs with short half-lives and
can be used to monitor drug as sustained release formulation as well as for delivering DNA
[8]. The dissolution rate of drug is enhanced, onset of therapeutic action is increased, and
the dose is reduced. The premature loss of drug through rapid clearance and metabolism
can also be prevented [6]. They also increase retention due to bio-adhesion.
Nanoscale  drug  delivery  systems  such  as  nanoparticles,  nanoliposomes,  dendrimers,
fullerence,  nanopores,  nanotubes,  nanoshells,  quantum  dots,  nanocapsule,  nanosphere,
nanovaccines,  nanocrystals  etc.  are  believed  to  have  potentials  to  revolutionize  drug
delivery systems. Further nanomaterials on chips, nano robotics, and magnetic nanoparti‐
cles attached to specific antibody, nanosize empty virus capsids and magnetic immunoas‐
say are new dimensions of their use in drug delivery. Thus nanomaterials can be used for
strategic development of new drug delivery systems and reformulating existing drugs to
enhance  the  effectiveness,  patent  protection,  patient-compliance,  safety  of  drugs  and
decreasing the cost of health care [9].
3. Various nanoscale drug delivery systems
3.1. Nanoparticles
Nanoparticles are submicron-sized polymeric colloidal particles with therapeutic agents of
interest encapsulated or dispersed within their polymeric matrix or adsorbed or conjugated
onto the surface. Commonly used synthetic polymers to prepare nanoparticles for drug
delivery are generally biodegradable [10]. Nanoparticles may also be composed of or transport
a variety of substances such as silica, gold or other heavy metals, medicaments, quantum dots,
nanocrystals, quantum rods and various contrast agents [11]. Nanoparticle systems offer major
improvements in therapeutics through site specificity, their ability to escape from multi-drug
resistance and the efficient delivery of an agent. They can be used for active drug targeting
attaching ligand such as antibody on their surface (Figure 1).
Solid lipid nanoparticles (SLNs) refer to as lipospheres or solid lipid nanospheres, or particles
and are generally solid at human physiological temperature (37oC) and have a diameter less
than 1000 nm [12]. They can be formed from a range of lipids, including mono-, di- and
triglycerides, fatty acids, waxes and combinations there of. SLNs must be stabilized by
surfactants to form administrable emulsions. SLNs form a strongly lipophilic matrix into which
drugs can be loaded for subsequent release. SLNs have been investigated for the delivery of
various cancer treatments like colon cancer, breast cancer [13].
Polymer-based nanoparticles have been extensively investigated as drug nanocarriers. The
most widely researched synthetic polymers include polylactide (PLA), poly (D,L-lactide-co-
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glycolide) (PLGA) and poly ethylene glycol (PEG). All three polymers are hydrolized in vivo
and are biodegradable. Other polymers based on biological polysaccharides have been
extensively investigated, including chitosan, Clycodextrin and dextrans [14].
Gold nanoparticles  (NPs)  consist  of  a  core  of  gold atoms that  can be  functionalized by
addition  of  a  monolayer  of  moieties  containing  a  thiol  (SH)  group.  Gold  NPs  can  be
synthesized using NaBH4 to reduce AuCL4-salts in the presence of thiol containing moieties
that  subsequently  form  a  monolayer  around  the  core  gold  atom,  depending  on  the
stoichiometric gold/ thiol ratio [15]. Drug delivery using gold NPs has been made in DNA
delivery for gene therapy and imaging [16]. PEG coated micelles containing drug are also
used  to  deliver  drug  as  new  delivery  system  (Figure  1).  Many  other  nanoparticulate
synthetic, semisynthetic, natural and metals are under investigation to know their poten‐
tials as drug delivery materials.
Polymeric nanoparticles may adhere to the cell surface and release drug molecules by diffusion
which may enter inside the cell to work. However the entire polymeric nanoparticles can also
enter the cell by endocytosis. They bind with the cell surface receptor and formation of
endosome takes place. Endosome may be lysed with the help of lysosomal enzymes and the
nanoparticles release in the cytoplasm (Figure 2).
Figure 1. Different Types of Nanocarriers for drug delivery
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Figure 2. Endocytosis mediated cellular internalization of drug nanocarriers
3.1.1. Nanoliposomes
Nanoliposomes are the nanosize vesicles made of bilayered phospholipid membranes
generally unilamellar with an aqueous interior (Figure 1) [17]. They can be used for the delivery
of low molecular weight drugs, imaging agents, peptides, proteins, and nucleic acids. Different
anticancer, antiviral drugs are incorporated within the liposomes [18]. Nanoliposomes can also
provide slow release of an encapsulated drug, resulting in sustained exposure to the site of
action and enhanced efficacy. Usually hydrophilic drugs can be loaded in aqueous compart‐
ment and lipophilic drugs are incorporated in the phospholipid layer [19]. However unlike
liposome nanoliposome does not undergo rapid degradation and clearance by liver macro‐
phages. As for the targeted drug delivery, nanoliposome plays an important role. It can be
used for passive targeting or active targeting [20]. Due to the leaky vascular structure of the
tumor tissue nanoliposomes get predominantly accumulated in the tumor and release the drug
for a prolonged period of time in passive targeting. Active targeting is achieved by incorpo‐
rating antibody, ligands etc. on the nanoliposomal surface. By active targeting liposomes
directly go to the targeted organs or tissues, and release drug for a prolonged period of time,
so that the normal cells are not affected and only the diseased cells are affected [21]. Targeted
nanoliposomal drug delivery is more efficacious than the non-targeted drug delivery systems.
C6-ceremide ligand induced nanoliposome used to treat the blood cancer directly targets the
over expressed lukemic cells and decreases the high epxpression of survivin protein in
leukemic cells [22]. The concept of long-circulating or sterically stabilized nanoliposomes is
derived for novelibility of delivery systems which can circulate in the blood for a long period
of time. Nanoliposomal formulations containing polyethylene glycol (PEG) alter the pharma‐
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cokinetic properties of various drug molecules leading to long elimination half-life [23].
Nanoliposomes are expected to bring lots of change in drug delivery in near future.
3.1.2. Dendrimers
Dendrimers are branched polymers, resembling the structure of a tree (Figure 1). Dendrimers
represent three dimensional highly branched polymeric macromolecules with the diameter
varying from 2.5 to 10 nm. It can be synthesized from both synthetic and natural monomers
e.g. aminoacids, monosaccharides and nucleotides. Two classes of dendrimers commonly used
for biomedical applications are polyamidoamines and polypropyleneimines [24]. A dendrimer
is typically symmetric around the core, and when sufficiently extended it often adopts a
spheroidal three-dimensional morphology in water. A central core can be recognized in their
structure with at least two identical chemical functionalities. Starting from those groups,
repeated units of other molecules can originate with at least one junction of branching. The
repetitions of chains and branching result in a series of radially concentric layers with increased
crowding [25].
The overall shapes of dendrimers range from spheres to flattened spheroids (disks) to amoeba-
like structures, especially in cases where surface charges exist and give the macromolecule a
‘‘starfish’’-like shape. Branching of dendrimers depends on the synthesis processes. Low
molecular weight drugs can be placed into the cavities within the dendrimer molecules and
are temporarily immobilized there with hydrophobic forces, hydrogen and covalent bonds
[26]. The two processes for the synthesis of dendrimers are divergent and convergent methods.
In the divergent method dendrimer grows outwords from a multifunctional core molecule.
The core molecule reacts with monomer molecules containing one reactive and two dormant
groups giving the first generation dendrimer. The convergent method is developed as a
response to the weakness of the divergent synthesis. In the convergent approach, the den‐
drimer is constructed stepwise, starting from the end groups and progressing inwards. When
the growing branched polymeric arms, called dendrons, are large enough, they are attached
to a multifunctional core molecule. The convergent method is relatively easy to purify the
desired product and the occurrence of defects in the final structure is minimised [27]. Due to
classical polymerization dendrimers have a negligible degree of polydispersity. They are
random in nature and produce molecules of various sizes. The size of dendrimers can be
carefully controlled during the process of synthesis of dendrimers. Scientists are focusing on
newer approaches for speeding up the synthesis process by preassembly of oligomeric
branches which can be linked together to reduce the number of synthesis steps involved and
also increase the dendrimer yield [28].
Dendrimers are popularly used for transfer of genetic materials in cancer therapy or other viral
diseases in different organs because of their monodisperisity, high density of functional
groups, well-defined shape and multivalency. In gene delivery polyamidoamines (PAMAM)
dendrimer is widely used. Some other types of dendrimers are peptide dendrimers, glyco‐
dendrimers, polypropilimine dendrimers, Polyethyleneimine (PEI) dendrimers etc.
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3.1.3. Nanoshells
Nanoshells (100-200 nm) may be used for drug carrier of both imaging and therapy. Nanoshells
consist of nanoparticles with a core of silica and a coating of thin metallic shell [29]. They can
be targeted to a tissue by using immunological methods. Nanoshells can also be embedded in
a hydrogel polymer [30]. Nanoshells are currently being investigated for prevention of
micrometastasis of tumors and also for the treatment of diabetes. Nanoshells are useful for
diagnostic purposes in whole blood immunoassays [31].
3.2. Fullerenes and nanotubes
Fullerenes composed of carbon in the form of a hollow sphere or ellipsoid tube. These are also
known as ‘bucky balls’ because of their resemblance to the geodesic dome design of Buck
minster Fuller. Fullerenes are being investigated for drug transport of antiviral drugs,
antibiotics and anticancer agents [32]. Fullerenes have the potential to stimulate host immune
response and productions of fullerene specific antibodies. Soluble derivatives of fullerenes
such as C60 have shown great utility as pharmaceutical agents.
Nanotubes are nanometer scale tube like structure and they are of different types like carbon
nanotube, inorganic nanotube, DNA nanotube, membrane nanotube etc. [33]. Carbon nano‐
tubes can be made more soluble by incorporation of carboxylic or ammonium groups to their
structures and can be used for the transport of peptides, nucleic acids and other drug mole‐
cules. The ability of nanotubes to transport DNA across cell membrane is used in studies
involving gene therapy. DNA can be attached to the tips of nanotubes or can be incorporated
within the tubes [34].
3.3. Nanopores
Nanopores (20 nm in diameter) consist of wafers with high density of pores which allow entry
of oxygen, glucose and other chemicals such as insulin to pass through. Nanopores can be used
as devices to protect transplanted tissues from the host immune system, at the same time,
utilizing the benefit of transplantation [35]. β-Cells of pancreas can be enclosed within the
nanopore device and implanted in the recipient’s body. Nanopores can also be employed in
DNA sequencing. Nanopores are also being developed with an ability to differentiate purines
from pyrimidines [36].
3.4. Quantum dots
Quantum dots (QD) are tiny semiconductor nanocrystals type of particles generally no larger
than 10 nanometers that can be made to fluoresce in different colours when stimulated by light.
The biomolecule conjugation of the QD can be modulated to target various biomarkers [37].
They can be tagged with biomolecules and used as highly sensitive probes. QD can also be
used for imaging of sentinel node in cancer patients for tumour staging and planning of
therapy. This technology also outlines some early success in the detection and treatment of
breast cancer [38]. QD may provide new insights into understanding the pathophysiology of
cancer and real time imaging and screening of tumors.
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Bioconjugated QD are collections of variable sizes of nanoparticles embedded in tiny beads
made of polymer material. In a process called “multiplexing,” they can be finely tuned to a
myriad of luminescent colors that can tag a multitude of different protein biomarkers or genetic
sequences in cells or tissues [39]. The new class of quantum dot conjugate contains an amphi‐
philic triblock copolymer layer for in vivo protection and multiple PEG molecules for improved
biocompatibility and circulation, making it highly stable and able to produce bright signals.
Another advantage is that quantum dot probes emitting at different wavelengths can be used
together for imaging and tracking multiple tumor markers simultaneously, potentially
increasing the specificity and sensitivity of cancer detection [40]. Recent progress in the surface
chemistry of QD has expanded their use in biological applications, reduced their cytotoxicity
and rendered quantum dots a powerful tool for the investigation of dinstinct cellular processes,
like uptake, receptor trafficking and intracellular delivery. Another application of QD is for
viral diagnosis. Rapid and sensitive diagnosis of Respiratory Syncytial Virus (RSV) is impor‐
tant for infection control and development of antiviral drugs. Antibody-conjugated nanopar‐
ticles rapidly and sensitively detect RSV and estimate relative levels of surface protein
expression. A major development is the use of dual-colour QD or fluorescence energy transfer
nanobeads that can be simultaneously excited with a single light source [41]. QD linked to
biological molecules, such as antibodies, have shown promise as a new tool for detecting and
quantifying a wide variety of cancer-associated molecules. In the field of nanomedicine, QD
can make a worthy contribution to the development of new diagnostic and delivery systems
as they offer unique optical properties for highly sensitive detection and they are well defined
in size and shape and can be modified with various targeting principles.
4. Applications of Nanoscale drug delivery systems
4.1. Nanotechnology for brain drug delivery
The blood brain barrier (BBB) is a structure formed by a complex system of endothelial cells,
astroglia, pericytes, and perivascular mast cells, preventing the passage of most circulating
cells and molecules [42]. The tightness of the BBB is attributed mainly to the vascular layer of
brain capillary endothelial cells which are interconnected side-by-side by tight and adherens
junctions. Among the different nanodevices, nanosize drug delivery systems between 1 and
100 nm work as a whole unit in terms of transport to cross BBB [43]. Nanosize brain drug
delivery systems may promote the targeting ability of drug in brain and at the same time
enhance the permeability of molecules through BBB. However crossing of BBB by the nano
drug carriers will depend completely on the physicochemical and biomimetic features and
does not depend on the chemical structure of drug, inside the nanoparticles [44]. Nanosize
drug carriers which do not cross BBB generally can be made “stealth” coated with some
polymeric materials or other chemicals to avoid the reticuloendothelial system, to display long
circulation time and stability in blood, and may be functionalized to successfully cross the BBB
and target brain [45].
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4.2. Nanosize drug carriers in ocular drug delivery
Drug loaded nanoparticles with favourable biological properties include prolonging the
residence time, decreasing toxicity and high ability of drug penetration into the deeper layers
of the ocular structure and minimizing precorneal drug loss by the rapid tear fluid turnover
[46]. Nanoparticles could target at cornea, retina and choroid by surficial applications and
intravitreal injection. Nanocarrier based drug delivery is suitable in the case of the retina, as
it has no lymph system, hence retinal neovascularisation and choroidal neovascularization
have similar environments to that of solid tumors, and the EPR effect as available for solid
nanoparticles in case of solid tumor may be also available for drug delivery targeted to eyes
by nanoparticles [47]. Nanoparticles can deliver ocular drugs to the target sites for the
treatment of various diseases such as glaucoma, corneal diseases, diabetic retinopathy etc. The
uses of nanotechnology based drug delivery systems like nanosuspensions, SLNs and
nanoliposomes have greater effect for ocular therapeutic efficacy [48]. Nanotechnology-based
drug delivery is also very efficient in crossing membrane barriers, such as the blood retinal
barrier in the eye.
4.3. Nanoparticle loaded contact lenses
Contact lenses loaded with nanoparticles can be effective for topical administration of
ophthalmic drugs. Drug loaded contact lenses can also provide continuous drug release
because of slow diffusion of the drug molecules through the lens matrix. The soaked contact
lenses also delivered drugs only for a period of few hours for some typical drugs [49]. The
duration of drug delivery from contact lenses can be significantly increased if the drug is first
entrapped in nanoformulations, such as nanoliposomes, nanoparticles, or microemulsions.
Such drug nanocarriers can then be dispersed throughout the contact lens material. The
entrapment of drug in nanocarriers also prevents the interaction of drug with the polymeri‐
zation mixture. This provides additional resistance to drug release, as the drug must first
diffuse through the nanocarriers and penetrate the drug carrier surface to reach the contact
lens matrix [50].
4.4. Biodistribution of nanoparticles in the retina
The ocular biodistribution of nanoparticles can provide insights into the bioavailability,
cellular uptake, duration of drug action and toxicity. Factors such as particle size, composition,
surface charge and mode of administration influence the biodistribution in the retinal struc‐
tures and also their drainage from the ocular tissues [51]. Larger particles (2 µm) were found
to remain in vitreous cavity near the trabecular meshwork from which they are discharged out
from the ocular tissue within 6 days, whereas the particles 200 nm were found evenly distrib‐
uted in the vitreous cavity, and the inner limiting membrane. The smaller particles ∼50 nm
crossed the retinal barriers, and was detected in the retina even after 2 months post injection
[52]. The surface chemistry can also affect nanoparticle distribution. Positively charged
nanoparticles can adhere to the anionic vitreous network components and aggregate within
the vitreous network. The surface chemistry can also affect nanoparticle distribution. Posively
charged nanoparticles can adhere to the anionic vitreous network components and aggregate
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within the vitreous humor [53]. Anionic nanoparticles were found to diffuse through the
vitreous humor and could even penetrate the retinal layers to be taken up by Muller Cells [54].
Vitreous humor is regarded as the barrier for non-viral ocular gene therapy because of the
strong interaction of conventional cationic nature of non-viral gene vectors with the anionic
vitreous humor [53]. The cationic PEI nanoparticles aggregated within vitreous humor and
were prevented from distributing to the retina by the vitreal barrier. In contrast, cationic glycol
chitosan (GC) nanoparticles and GC/PEI blended nanoparticles could penetrate the vitreal
barrier and even reach at the inner limiting membrane because of the existence of glycol groups
on nanoparticles [55].
4.5. Nanoparticles in cancer
Cancer cells are more vulnerable than normal cells to the effect of chemotherapeutic agents
and the most of the anticancer drugs can cause injury to the normal cells. Optimum dose and
frequency are both important factors in the persistence of cancer cells during cancer chemo‐
therapy [56]. Now attempts are focused on efforts to kill cancer cells by more specific targeting
while sparing the normal cells.
Nanoparticulate delivery systems in cancer therapies provide better penetration of therapeutic
and diagnostic substances within the cancerous tissue in comparison to conventional cancer
therapies [57]. Nanoparticles are constructed to take advantages of fundamental cancer
morphology and modes of development such as rapid proliferation of cells, antigen expres‐
sion, and leaky tumor vasculature. Nanoparticulate drug delivery systems are being devel‐
oped to deliver smaller doses of chemotherapeutic agents in an effective form and control drug
distribution within the body [58]. Nanocarriers can offer many advantages over free drugs in
cancer chemotherapy such as they protect the drug from premature degradation, prevent
drugs from prematurely interacting with the biological environment, enhance absorption of
the drugs into a selected tissue (solid tumour), control the pharmacokinetic and drug tissue
distribution profile and improve intracellular penetration [59].
Nanoparticulate delivery systems utilize specific targeting agents for cancer cells minimizing
the uptake of the anticancer agent by normal cells and enhance the entry and retention of the
agent in tumor cells (Figure 3) [60]. Nanocarriers may actively bind to the specific cancer cells
by attaching targeting agents with the help of ligand molecules to the surface of the nanocar‐
riers that bind to specific receptor antigens on the cell surface. Nanocarriers will recognize and
bind to target cells through ligand receptor interactions. It is even possible to increase the drug
targeting efficacy with the help of antibodies by conjugating a therapeutic agent directly to it
for targeted delivery [61].
Like receptor targeting, targeting of angiogenic factors also takes advantage of properties
unique to cancer cells. Anti-angiogenic treatment is the use of drugs or other substances to
stop tumors from developing new blood vessels. In a study nanoparticles were formulated
comprising a water-based core of Vickers microhardness sodium alginate, cellulose sulphate,
and anti-angiogenic factors such as thrombospondin (TSP)-1 or TSP-517, crosslinked with
dextran polyaldehyde with calcium chloride or conjugated to heparin sulphate with sodium
chloride. In addition bioluminescent agent, luciferase, or contrast agent, polymeric gadolinium
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was located within the polyanionic core [62] for drug targeting and detection. Similarly, many
efforts are on for cancer cell targeting specifically with drug nanocarriers.. Thus the drug
nanocarriers are of great hope for future cancer therapy.
Figure 3. Schematic diagram of nanoparticle permeation and retention effect in normal and tumour tissues. Normal
tissue vasculatures are lined by tight endothelial cells, hereby preventing nanoparticulate drug delivery system from
escaping, whereas tumor tissue vasculatures are leaky and hyperpermeable allowing preferential accumulation of
nanoparticles or nanoliposomes in the tumor interstial space by passive targeting
4.6. Gene delivery
Transfer of genetic material in nanocarriers may be an approach for the treatment of various
genetic disorders such as diabetes mellitus, cystic fibrosis, alpha 1 antitrypsin deficiency and
may more. A number of systemic diseases are caused by lack of enzymes factors that are due
to missing or defective genes [63]. Previously gene therapy which was used to treat genetic
disorders nowadays being contemplated as carrier systems which could be implanted for
combating diseases other than genetic disorder like malignant form of cancer, heart diseases
and nervous diseases [64]. Nanoliposomes can be used to deliver genetic materials into cells.
Nanoliposomes incorporated with PEG and galactose target liver cells effectively due to their
rapid uptake by liver Kupffer cells. Gene therapy may be tried with liposomal nanocarriers
for liver disorders such as Wilson’s and hereditary hemochromatosis. Cationic nanoliposomes
have been considered as potential non-viral human gene delivery system [65]. Another
effective method for administering nanoliposomes is by using ligand receptor complex using
EGF-EGFR system for targeting purpose by nanoliposomes where EGF is a small protein which
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binds with receptor EGFR. Also mixing cationic lipids with plasmid DNA leads to the
formation of lipoplexes where the process is driven by electrostatic interactions [66]. The
negatively charged genetic material (e.g. plasmid) is not encapsulated in nanoliposomes but
complexed with cationic lipids by electrostatic interactions. Plasmid liposome complexes can
enter the disease cells by infusion with the plasma or endosome membrane. Allovectin-7 (gene
transfer product) is composed of a plasmid containing the gene for the major histocompatibility
complex antigene HLA-B7 with B2 microglobulin formulated with the cytofectin [67]. The
nature of a composed lipid decides the unloading of the gene from nanoliposomes which
enables control over the mode of release, doping of nanoliposomes with neutral lipids such as
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) which helps in endosomal mem‐
brane fusion by recognizing and destabilizing the phospholipids in a flip flop manner which
paves way for the liposomes to integrate in the membrane with the dissociation of nucleic acid
into the cytoplasm [64].
Viral system based gene carrier had the ability to overcome the biological barriers in the
body  and  then  access  to  the  host  nucleus  replicative  machinery  which  resulted  in  the
exploitations  of  the  system  for  drug  delivery  using  nanotechnology  [64].  The  develop‐
ment of a non-viral method for in vivo gene transfer was designed where the vector was
packed into compact nanoparticles by successive additions of oppositely charged polyelec‐
trolytes including an incorporation of ligands into the DNA-polyelectrolyte shells  which
were mixed with Pluronic F127 gel serving as a biodegradable adhesive to keep shells in
contact with the targeted vessel [68].
A novel method of gene delivery is with viruses such as adeno associated virus (AAV) which
have their virulent genes removed with lentiviruses, clearly showing their efficiency [64].
8. Drug delivery with the help of empty virus capsid
The viral nanoparticles (VNPs) consist of protein core which ranges in complexity from small
capsid-protein homomers to larger protein-based heteromers capable of internalizing oligo‐
nucleotides and being enveloped by lipids. Chemical modification process and genetic
mutation provide the viral coat proteins with receptor binding domain that helps in cell specific
targeting of VNPs [69]. Even fusion of terminal / internal proteins on the surface or inside the
VNPs can be utilized for introduction of heterologous peptides, and in some cases entire
proteins. VNPs can be genetically engineered by inserting amino acids for bioconjugation,
peptide based affinity tags and peptides as targeting ligands for stimulation of immune
response. [70].
High sequence variability due to the influence of the immune system in viral life-cycles is often
seen on the surface loops of viral capsid proteins. This variability makes the loops highly
susceptible to insertion of foreign sequences. VP1, the major coat protein of viruses of Polyo‐
maviridae family, when expressed in insect cells, yeast and Escherichia coli self-assembles as
protein cages and shows natural affinity for a cell surface glycoprotein with a terminal a 2,3-
linked N-acetylneuraminic acid and attaches to a4h1-integrin receptors [71]. Virus like particle
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(VLPs) constructed from the virus are used to deliver therapeutic genes to human fetal glial
cells. Another technique Cell-docking involves attachment of antibodies to the surface of brain
natriuretic peptide (BNPs). Coupling reaction between murine polyoma-virus and antitumor
antibody B3 yielded polyoma VLPs with 30 to 40 antibody fragments bound to the surface,
allowing the modified VLPs to bind to the breast carcinoma cells with high efficiencies [72].
9. A glimpse to future of nanosize drug delivery systems
Advancement of nanosize drug delivery systems establishes a new paradigm in pharmaceut‐
ical field. Convergence of science and engineering leads a new era of hope where medicines
will act with increase efficacy, high bioavailability and less toxicity. Several nanoscale drug
delivery systems are currently in clinical trials and few of them are already commercially
available. Examples of such products are Abeicet (for fungal infection), Doxil (antineoplastic),
Abraxane (metastatic breast cancer), Emend (antiemetic) etc. Despite the impressive progress
in the field, very few nanoformulations have been approved by US-FDA (United States Food
and Drug Administration) and even reached market in recent years. Although nanocarriers
have lots of advantages because of the unique properties they have, there are many clinical,
toxicological and regulatory aspects which are the matters of concern too. The biocompatibility
of nanomaterials is of atmost importance because of the effect of the nanomaterials in the body
ranging from cytotoxicity to hypersensitivity [8]. With the advancement of nanotechnology,
the biological phenomenon such as host response to a specific nanomaterial should also be
clinically transparent [9]. Therefore it is quite essential to introduce cost effective, better and
safer nanobiomaterials which will provide efficient drug loading and controlled drug release
of some challenging drug moieties for which there is no other suitable delivery available yet.
Nanoliposomes are well developed and presently possess the highest amount of clinical trials
among other nanomaterials with some formulations currently in the market. This may be due
to the fact that other materials have not been investigated for the same duration and are
relatively newer in comparison. However polymer based nanomaterial, carbon nanotubes,
gold nanoparticles etc. should not be overlooked because of less number of clinical trials [7].
Genexol-PM is an example which was undergone recent clinical trial. This is an amphiphilic
diblock co-polymer (PEG-D, L-Lactic acid) that delivers paclitaxel. Clinical trial currently is in
phase IV using Genexol-PM for recurrent breast cancer and phase III for breast cancer. Fungal
infections associated with acute leukemia and for central line fungal infections, amphotericin
B containing nanoliposomes are in phase IV clinical trial. ThermoDox (Doxorubicin loaded
nanoliposome) is currently in phase III trials for hepatocellular carcinoma. Similarly Caelyx,
a doxorubicin HCl loaded nanoliposome that is pegylated, is currently in phase IV trials for
ovarian neoplasms [7]. Some recent clinical trials are shown in Table 1.
Ligand or antibody conjugated nanoformulation, bifunctional and multifunctional nanopar‐
ticles are the newer research approaches through which detection and treatment of cancerous
cells can be achieved. Nanomachines are also largely in the research-and-development phase,
but some primitive molecular machines have been tested. An example is nanorobot which is
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capable of penetrating the various biological barriers of human body to identify the cancer
cells. Thus, nanodrug delivery systems have a leading role to play in nanomedicine in near
future.
Product name Delivery material Phase Condition TherapeuticDelivered Sponsor
Clinicaltrials. gov
Identifier
Genexol-PM
Amphilic diblock
Copolymer forming
micelle
I Non smallCell lung cancer Paclitaxel
Samyang
Biopharmaceutical
Corp
NCT01023347
Docetaxel-PNP Polymericnanoparticles I
Advanced solid
malignancies Docetaxel
Samyang
Biopharmaceutical
Corp
NCT01103791
CYT-6091 AuNP I Unspecified adultsolid tumor TNF NCI NCT00356980
Paclitaxel
poliglumex
Drug Polymer
Conjugate II Prostate cancer Paclitaxel
OHSU Knight Cancer
Institute NCT00459810
Kogenate FS PEG-liposome I Hemophilia A Recombinantfactor VIII Bayer NCT00629837
Long-circulating
liposomal
prednisolone
disodium
phosphate
Liposome II Rheumatoidarthritis Prednisolone Radboud University NCT00241982
LE-DT Liposome II Pancreatic cancer Doxetaxel Insys Therapeutics Inc NCT01186731
Cisplatin and
Liposomal
Doxorubicin
Liposome I Advanced cancer Cisplatin anddoxorubicin
M.D. Anderson Cancer
Center NCT00507962
Liposomal
doxorubicin
and bevacizumab
Liposome II Kaposi’s sarcoma Doxorubicin andbevacizumab NCI NCT00923936
AP5346 Drug polymerconjugate
Not
stated
Head and neck
cancer
AP5346 and
oxaliplatin
University of
California, San
Diego
NCT00415298
Abbreviations: PEG-Polyethylene glycol, TNF-Tumor necrosis factor, NCI-National Cancer Institute, AuNP-Gold nanoparticles
Table 1. Recent Nanodrug Carriers in Clinical Trials (Source: Clinicaltrials.gov)
Nanocarriers may lead to a solution to major unsolved medical problems which will aggres‐
sively enhance quality of life.
Regulatory aspect: One of the main areas related to the safety aspects of drug-nanocarrier
systems is to encourage academic organizations, industry and regulatory governmental
agencies to establish convincing testing procedures on the safety aspects of the nanomaterials.
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The global importance of trade for nanomaterials has established new international organiza‐
tions, such as the International Council on Nanotechnology (ICON), the International Organ‐
ization for Standardization (Geneva, Switzerland) etc. for sharing responsibilities in this field.
In the year 1996 the NNI was established in the United States of America to coordinate
governmental multi-agencies such as the Food and Drug Administration (FDA), the Depart‐
ment of Labor through the Occupational Safety and Health Administration (OSHA), the
National Institute for Occupational Safety and Health (NIOSH), and the Environmental
Protection Agency (EPA), for the development of nanoscience and technology.
10. Conclusion
Last few years several new technologies have been developed for the treatment of various
diseases. The use of nanotechnology in developing nanocarriers for drug delivery is bringing
lots of hope and enthusiasm in the field of drug delivery research. Nanoscale drug delivery
devices present some advantages which show higher intracellular uptake than the other
conventional form of drug delivery systems. Nanocarriers can be conjugated with a ligand
such as antibody to favor a targeted therapeutic approach. The empty virus capsids are also
being tried to use for delivering drugs as a new therapeutic strategy. Thus, nanoscale size drug
delivery systems may revolutionize the entire drug therapy strategy and bring it to a new
height in near future. However, toxicity concerns of the nanosize formulations should not be
ignored. Full proof methods should be established to evaluate both the short-term and long-
term toxicity analysis of the nanosize drug delivery systems.
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